Patent ID: 8716251
Filing Date: 2014-05-06
Classification: A61K,A61P

Abstract:
1. An immediate release pharmaceutical formulation comprising a dapagliflozin propylene glycol hydrate selected from the (S)-propylene glycol hydrate having the formula and the (R)-propylene glycol hydrate having the formula and a pharmaceutically acceptable carrier, in a form selected from the group consisting of a tablet, a stock granulation, and a capsule, wherein the dapagliflozin propylene glycol hydrate is present in an amount to provide a daily dose within the range of from about 0.1 to about 750 mg per day in single or divided doses or multiple doses, which is administered 1 to 4 times, wherein the dapagliflozin propylene glycol hydrate is present in an amount within the range of from 0.1% to 70% of tablet or capsule fill; and the pharmaceutically acceptable carrier comprises: